Next Safety Announces Bid Date for the Sale of the Company’s Platform for the Pulmonary Delivery of Albuterol and the Components of Advair(TM)

JEFFERSON, N.C., Dec. 22 /PRNewswire/ — Next Safety has developed a
proprietary platform that delivers nicotine and a number of other drugs
including albuterol and the components of Advair(TM), fluticasone propionate
and salmeterol xinofoate, in air timed to the user’s inhalation. Certain US
patents for the chemical components of Advair(TM) expired September 2008.

Next Safety’s platform has numerous advantages over current methods used
for delivering these significant asthma medications. The benefits include the
use of air instead of refrigerant-based propellants and the delivery of
medication timed to the user’s inhalation, unlike dry powder inhalation
devices.

(http://tinyurl.com/68twd7)

NSI has decided to sell intellectual property and other related assets for
the pulmonary delivery of certain asthma medications, utilizing its
proprietary platform, in a competitive bidding process that includes a number
of leading, global pharmaceutical companies.

According to Eric Hunter, CEO of Next Safety, “We are selling the assets
related to the pulmonary delivery of albuterol, fluticasone and salmeterol in
a bid process that ends February 12, 2009.”

    Photos:

http://www.ereleases.com/pr/2008-NextSafety.jpg

http://www.ereleases.com/pr/2008-NextSafety2.jpg

    Website: http://www.nextsafety.com

    Contact:
    George Colvard, COO Next Safety, georgecolvard@nextsafety.com
    Philip Weaver, President Next Safety, philipweaver@nextsafety.com

This release was issued through eReleases(TM). For more information,
visit http://www.ereleases.com.

SOURCE Next Safety, Inc.